Balyasny Asset Management LLC Biomarin Pharmaceutical Inc Call Options Transaction History

Balyasny Asset Management LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $2.05 Million - $2.79 Million	29,700 Added 146.31%	50,000 $3.51 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $1.51 Million - $1.87 Million	20,300 New	20,300 $1.67 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $7.62 Million - $9.85 Million	100,000 New	100,000 $9.64 Million
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $3.41 Million - $4.24 Million	-47,000 Reduced 47.0%	53,000 $4.65 Million
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $3.98 Million - $6.21 Million	50,000 Added 100.0%	100,000 $12.3 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $25.6 Million - $29.9 Million	-318,700 Reduced 86.44%	50,000 $4.4 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $28 Million - $36.5 Million	368,700 New	368,700 $34.7 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.